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Summary Lansoprazole uptake sites by two kinds of autoradiographic procedures were
compared with recent literature. The uptake sites have been seen in the Helicobacter pylori,
colonic epithelial cells, inflammatory cells, peripheral autonomic nerves and entero-
chromaffinlike cells as well as gastric parietal cells. Each uptake sites corresponded to the
reported localization of P-type ATPase or acidic compartment.
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Introduction
In almost all biological system, ATP is used as an energy
source. As most cells are impermeable to ATP, it must be
recycled in each cell. As a consequence, every cell catalyses
an ATP synthesis/ATP hydrolysis cycle. A diverse ATPases
runs this system; at least three classes are ion motive
ATPases; phosphorylated (P), vacuolated (V) and F0F1 (F)
types [1].
The gastric H, K-ATPase is a member of the P-type, ion-
motive ATPase gene family. In eukaryotes, other members
of the family are the Na, K-ATPases, the Ca ATPases of
sarcoplasmic reticulum, endosome and plasma membrane,
and the fungal H-ATPases [2, 3].
As to the H, K-ATPase, it is clear that the expression of the
genes encoding the two subunits of the gastric H, K-ATPase
is not restricted to the stomach. Furthermore, a number of
closely related H, K-ATPase isoforms have been discovered.
These isoforms are also expressed in several organs including
distal colon and distal tubule of kidney [4].
Substituted benzimidazoles, omeprazole, lansoprazole, panto-
prazole and rabeprazole have been one of the World’s top
selling drugs because of its effectiveness to gastroduodenal
ulcers, gastroesophageal reflux diseases, specificity of the
effector sites and safety. Its specificity is based on the
characteristics that this agent is a prodrug of sulfenamide
and accumulates in the acidic compartment and converted to
the rather impermeable sulfenamide and binds covalently to
cysteine accessible from the extracytoplasmic face of the
enzyme [5]. This means that acidic environment with cysteine
residues in the luminal surface could be novel targets of this
agents and their derivatives.
We have performed the autoradiography using tritiated
lansoprazole for the last twelve years. This paper was
attempted to review recent publications related to ATPases
and substituted benzimidazoles and clarify the significance
of our autoradiographic observation.
Autoradiographic Procedures Used in This Study
To clarify the localization of the water-soluble compounds,
two kinds of autoradiographic procedures are available, i.e.,
autoradiography of soluble compounds and in vitro auto-
radiography using unfixed cryostat sections.
Nagata et al., [6] started the autoradiography of water
soluble or diffusible compounds in 1969. This method is the
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combination of administration of radiolabelled compounds,
freeze-drying of the tissue, fixation with osmium vapor, direct
Epon embedding under low temperature, tissue sectioning
with ethylene glycol instead of water and application of
autoradiographic emulsion film by wire-loop method. After
30 to 60-day exposure, the specimens were developed and
fixed. Using this method, we could identify the uptake or
binding sites of the radiolabelled chemicals by light and
electron microscopy [7, 8].
The second method is composed of cryostat sectioning of
the unfixed tissues, administration of the radiolabelled
compounds and application of autoradiographic emulsion films
by the wire-loop method. In this method, the specimens can
be observed by light microscopy and double staining with
immunohistochemical method is available [9].
In this context, omeprazole and lansoprazole are very
useful tools to clarify their uptake sites, because they are
accumulated in the acidic compartment and binds covalently
to the cysteine residues as mentioned above and become
insoluble to water. Thus, the ordinary autoradiographic
method can be applied which is used in 3H-thymidine
autoradiography, because administered 3H-thymidine also
becomes insoluble to water after incorporated to the DNA.
The specificity of the uptake sites of omeprazole and
lansoprazole could be estimated by the prior administration of
glutathione. This procedure is able to inhibit the accumulation
of the compounds [10].
Uptake Sites in the Fundic Mucosa
In the healthy fundic mucosa, most of the uptake sites are
the parietal cells (Fig. 1). The relatively young parietal cells
localized in the neck portion of the funded glands show the
strongest accumulation, while in the body and base of the
funded glands the accumulation was not so strong. In
addition, some of the uptake sites are recognized in the
enterochromaffinlike cell and other neuroendocrine cells.
These uptake sites could represent the same kind of P-type
ATPases as reported to exist in the chromaffin cells and
cholinergic nerves [11].
Uptake Sites in Helicobacter pylori-Infected Mucosa
The uptake sites of PPIs in the Helicobacter pylori (H.
pylori)-infected gastric mucosa can be divided into H. pylori
itself and background mucosal tissues.
As to the activity of substituted benzimdazoles against
H. pylori, Megraud et al. [12] reported the bacteriostatic
effect of lansoprazole and omeprazole but not against C. jejuni
or E. coli. The MICs was lower for lansoprazole than for
omeprazole (16 vs 64 mg/l). Following this paper, members
of the Takeda pharmaceutical have reported many interesting
papers. At first they showed the inhibition of H. pylori urease
activity by lansoprazole [13, 14], while in the later papers
they found the activity of lansoprazole was fourfold more
potent than that of omeprazole and bismuth subsalicylate, with
MICs ranging from 1.56 to 25 micrograms/ml and concluded
that anti-H. pylori effect is not by sulfenamide, because the
antibacterial activity of omeprazole and lansoprazole was
not affected by glutathione or dithiothreitol, which completely
abolished the inhibitory activity of lansoprazole against H.
pylori urease [15, 16].
As to the effect of other substituted benzimidazoles,
omeprazole and rabeprazole to H. pylori, both of the urease
dependent and independent mechanisms have been postulated
[17–19]. As to this non-sulfenamide-mediated anti-H.
pylori effect of proton pump inhibitors, the sulfides of
benzimidazoles was reported to show the selective and
reversible antibacterial effect without any covalent protein
Fig. 1.  Lansoprazole uptake sites in rat fundic mucosa and
isolated parietal cells. Autoradiography of soluble
compounds. a, b: Uptake sites are accumulated in the
parietal cells. c: Electron microscopic autoradiograph
showing that the silver grains showing the uptake sites
are accumulated near the intracellular canaliculi of the
parietal cell. d: In the isolated parietal cells, silver grains
are recognized in the intracellular canaliculi. e, f: In the
base of the fundic glands, silver grains are accumulated
in the enterochromaffin-like cells.M. Nakamura et al.
J. Clin. Biochem. Nutr.
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binding [20].
As to the urease activity of H. pylori, not only the surface
bound urease but UreI existing between two layers of
bacterial membrane has also reported to play more significant
role in the survival of H. pylori, and this enzyme system was
suggested to be a new target of drug therapy [21].
As to the pharmacological foci of H. pylori other than
urease, the existence of P-type ATPases has been suggested
[22–24]. One of these enzymes was shown to be heavy
metal cation, cupper and nickel, transporting ATPase and
belongs to a family of P-type ATPases containing eight
transmembrane segments. This enzyme was reported to have
relation to bacterial resistance to heavy metals [25] and
exists also in Streptomyces species [26]. More recently, this
enzyme has shown to be related to bacterial adaptation to the
environment and type IV-related secretory mechanism of
Cag A [27–30].
As to the formation of the autoimmune gastritis, the
molecular mimicry of H. pylori and the parietal cells have
been pointed out. Recently, this is found to be related to the
H, K-ATPase in the parietal cells [31, 32].
Other ATPase system reported in H. pylori is the flagellar-
specific ATPase (Fli1) [33] and V-type ATPase related to vac
A [34].
Our autoradiographic study has shown the existence of
uptake sites of 3H-lansprazole near the plasma membrane of
the H. pylori (Fig. 2) [35]. This localization could be related
one of these enzymes described above.
Uptake Sites in the Colonic Mucosa
There are sites other than fundic mucosa in the body to be
able to reabsorb K and secrete H, such as the distal colon and
the distal tubule of the kidney.
Kaunitz et al. [36] reported the existence of two kinds of
colonic ATPases by the pharmacological method. One was
similar to H, K-ATPase, while the colonic transporter in the
intact organ was ouabain inhibitable, in contrast to the H,
K-ATPase [37]. The sequence of the colonic APTase is 75%
homologous to the H, K-ATPase in the parietal cell [38]. A
K-ATPase has been shown to be present in a colon cancer
cell line and be related to drug resistance [39, 40]. It would
appear that there is yet another family of P-type ATPases,
those with sequences intermediate between the Na, K- and
H, K-ATPases and suggested to have different inhibition
characteristics [41]. The cloned colonic ATPase does not
have the extracytoplasmic cisterns reacting with omeprazole,
and the loop between M1 and M2 is not identical with the
gastric H, K-ATPases.
Through our autoradiographic studies using 3H-lansoprazole,
we have obtained two diverse uptake sites in the colonic
mucosa. By the in vivo administration followed by auto-
radiography of soluble compounds, the uptake sites were
mostly found in the upper colonic epithelial cells in the control
rats (Fig. 3) [8], while in the in vitro autoradiography using
unfixed cryostat sections, most of the uptake sites were
found in the inflammatory cells including polymorphonuclear
leucocytes and macrophages and in the colonic epithelial
cells in the control and dextran sulfate sodium (DSS)-treated
rats [9]. Because of the different method of fixation, this may
be due to the stability of the enzyme in the inflammatory
cells. The clinical relevance to this observation is not clear,
but some reports showed the effectiveness of omeprazole to
the ulcerative colitis [42] and DSS-induced colitis [9].
Fig. 2.  Lansoprazole uptake sites in H. pylori-infected gastric
mucosa. a, b: In H. pylori-infected Mongolian gerbil
fundic mucosa (a), the uptake sites of lansoprazole are
seen in the inflammatory cells in the lamina propria
mucosa as well as parietal cells and H. pylori, while in
the control gerbils the uptake sites are accumulated in
the luminal side of the parietal cells. Autoradiography of
soluble compounds. c: By in vitro autoradiography using
unfixed cryostat sections of the Mongolian gerbil fundic
mucosa, the uptake sites are seen near the surface epithelial
cells and inflammatory cells (arrows). d, e: By Electron
microscopic autoradiography of soluble compounds, the
uptake sites are accumulated in the H. pylori (d) as well
as inflammatory cells (e).Lansoprazole Novel Effector Sites
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Uptake in Inflammatory Cells
From the above observation, the relation of lansoprazole
to the inflammatory cells has been suggested, while few
reports have shown the existence of P-type ATPase in the
inflammatory cells and V-type ATPase was proved to be
existing through the effect of bafilomycin [43]. The pH of
lysosome is generally thought to be about 5 and can be a
candidate for the accumulation of substituted benzimidazole,
especially lansoprazole, because it has two pKas and one is
slightly shifted to the neutral pH, compared with omeprazole
[44].
Relation to Other Bacteria
The benzimdazoles are found to be bacteriocidal to oral
bacteria, Streptococcus mutans, Fusobacterium nucleatum
and Prevotella intermedia in acidic environment [45]. In these
bacteria, identified targets for benzimidazole inhibition
included the phosphoenolpyruvate sugar phosphotransferase
system, the glycolytic enzymes aldolase, glyceraldehyde-3-
phosphate dehydrogenase, and lactic dehydrogenase, and
enzymes such as urease and arginine deaminase.
Uptake in Fungus and Yeast
The yeast plasma membrane proton pumping ATPase (H-
ATPase) is a potential molecular target for antifungal drug
therapy by examining the inhibitory effects of the sulfhydryl-
reactive reagent omeprazole on cell growth, glucose-
induced medium acidification and H-ATPase activity [46].
Omeprazole inhibited the growth of Saccharomyces cerevisiae
and the human pathogenic yeast Candida albicans in a pH
dependent manner.
Uptake Sites in the Esophagus
We have observed the uptake sites of lansoprazole in the
esophagus and found mostly in the peripheral autonomic
nervous system. By the immunohistochemical observation,
most of them coincided with CGRP-immunoreactive nerves.
Pharmacological studies have demonstrated the effect of
lansoprazole on the increased bicarbonate secretion [47] and
autonomic nerve-mediated regulation was suggested. As to
the autonomic nerves, existence of P-type ATPase has been
reported in the cholinergic and adrenergic nerves [11, 48]
and this is a functional protein system containing a critical
sulfhydryl group.
Possible Uptake in Kidney, Placenta and Others
In rat kidney, sequence information has shown the presence
of gene products identical with the gastric H, K-ATPase [49,
50]. There has also been biochemical evidence described
showing the presence of a K-ATPase in the kidney that is
different from the Na, K-ATPase. In placenta, non-gastric H,
K-ATPase is present in the microvillous plasma membrane
of the transporting epithelia of the human placenta [51]. In
addition, fibroblasts [52] and endothelial cells [53] could be
possible candidates.
Conclusions
The effectiveness of substituted benzimidazoles seems to
be clinically obvious, but we still have a long way to go to
draw the whole map of this interesting agent especially its
relation to various kinds of ATPases.
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